If approved, AstraZeneca and Daiichi Sankyo’s ENHERTU will potentially be the first HER2-directed treatment and antibody drug conjugate to receive a tumor-agnostic indication
Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data
Submission to be reviewed under FDA Real-Time Oncology Review and Project Orbis
https://finance.yahoo.com/news/enhertu-fam-trastuzumab-deruxtecan-nxki-120000780.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.